DDInter946 DDInter1619
Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon-
Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome . In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole .
Interferon alfacon-1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ropinirole
Interferon alfacon-1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Simvastatin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ropinirole
Interferon alfacon-1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) downregulates {v} (Gene) USP22
USP22 {u} (Gene) is downregulated by {v} (Compound) Ropinirole
Interferon alfacon-1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) causes {v} (Side Effect) Renal failure acute
Renal failure acute {u} (Side Effect) is caused by {v} (Compound) Ropinirole
Interferon alfacon-1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Colchicine
Colchicine {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Ropinirole
Interferon alfacon-1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Dermatitis bullous {u} (Side Effect) is caused by {v} (Compound) Ropinirole
Interferon alfacon-1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Simvastatin {u} (Compound) downregulates {v} (Gene) GTF2A2
GTF2A2 {u} (Gene) is upregulated by {v} (Compound) Ropinirole
Interferon alfacon-1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} (Compound) downregulates {v} (Gene) USP22
USP22 {u} (Gene) is downregulated by {v} (Compound) Ropinirole
Interferon alfacon-1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Simvastatin {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is downregulated by {v} (Compound) Ropinirole
Interferon alfacon-1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Levodopa {u} (Compound) palliates {v} (Disease) restless legs syndrome
restless legs syndrome {u} (Disease) is palliated by {v} (Compound) Ropinirole
Interferon alfacon-1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ropinirole (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ropinirole (Compound)
Interferon alfacon-1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Ropinirole (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) causes Renal failure acute (Side Effect) and Renal failure acute (Side Effect) is caused by Ropinirole (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Colchicine and Colchicine (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Ropinirole (Compound)
Interferon alfacon-1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) causes Dermatitis bullous (Side Effect) and Dermatitis bullous (Side Effect) is caused by Ropinirole (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin (Compound) downregulates GTF2A2 (Gene) and GTF2A2 (Gene) is upregulated by Ropinirole (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Ropinirole (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is downregulated by Ropinirole (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa (Compound) palliates restless legs syndrome (Disease) and restless legs syndrome (Disease) is palliated by Ropinirole (Compound)